Trial Profile
Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Dec 2019 Status changed from active, no longer recruiting to completed as per the results presented at the American Heart Association Scientific Sessions 2019.
- 18 Nov 2019 Primary endpoint (Difference in change in carotid plaque volume) has not been met, as per results presented at the American Heart Association Scientific Sessions 2019.
- 18 Nov 2019 Results presented at the American Heart Association Scientific Sessions 2019